Trial Profile
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Omarigliptin (Primary) ; Glimepiride; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 09 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Sep 2013 Planned End Date changed from 1 Oct 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.